# Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance

> **NCT01237899** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 32 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** LY2623091
- **DRUG:** Placebo
- **DRUG:** Eplerenone

## Key facts

- **NCT ID:** NCT01237899
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01237899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01237899, "Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01237899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*